

IMMUNOGEN INC

Form 3

December 16, 2016

FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIESFiled pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting
Person *

Wingrove Theresa

(Last)

(First)

(Middle)

2. Date of Event Requiring
Statement

(Month/Day/Year)

12/09/2016

3. Issuer Name **and** Ticker or Trading Symbol
IMMUNOGEN INC [IMGN]4. Relationship of Reporting
Person(s) to Issuer5. If Amendment, Date Original
Filed(Month/Day/Year)

(Check all applicable)

☐ Director ☐ 10% Owner
☒ Officer ☐ Other
(give title below) (specify below)
VP of Regulatory Affairs6. Individual or Joint/Group
Filing(Check Applicable Line)
☒ Form filed by One Reporting
Person
☐ Form filed by More than One
Reporting PersonC/O IMMUNOGEN, INC., 830
WINTER STREET

(Street)

WALTHAM, MA 02451

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned1. Title of Security
(Instr. 4)2. Amount of Securities
Beneficially Owned
(Instr. 4)3. Ownership
Form:
Direct (D)
or Indirect
(I)
(Instr. 5)4. Nature of Indirect Beneficial
Ownership
(Instr. 5)Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form displays a
currently valid OMB control number.****Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**1. Title of Derivative
Security
(Instr. 4)2. Date Exercisable and
Expiration Date
(Month/Day/Year)Date Exercisable Expiration
Date3. Title and Amount of
Securities Underlying
Derivative Security
(Instr. 4)Title Amount or
Number of
Shares4. Conversion
or Exercise
Price of
Derivative
Security5. Ownership
Form of
Derivative
Security:
Direct (D)
or Indirect
(I)6. Nature of Indirect
Beneficial
Ownership
(Instr. 5)

(Instr. 5)

Stock Option (right to buy)	01/18/2012 ⁽¹⁾	01/18/2021	Common Stock	37,500	\$ 9.85	D	Â
Stock Option (right to buy)	07/22/2012 ⁽²⁾	07/22/2021	Common Stock	20,000	\$ 15.2	D	Â
Stock Option (right to buy)	07/20/2013 ⁽³⁾	07/20/2022	Common Stock	40,000	\$ 15.83	D	Â
Stock Option (right to buy)	07/16/2014 ⁽⁴⁾	07/16/2023	Common Stock	40,000	\$ 19.02	D	Â
Stock Option (right to buy)	07/17/2015 ⁽⁵⁾	07/17/2024	Common Stock	40,000	\$ 10.79	D	Â
Stock Option (right to buy)	07/13/2016 ⁽⁶⁾	07/13/2025	Common Stock	48,000	\$ 16.72	D	Â
Stock Option (right to buy)	06/01/2017 ⁽⁷⁾	06/01/2026	Common Stock	4,000	\$ 5.75	D	Â
Stock Option (right to buy)	07/18/2017 ⁽⁸⁾	07/18/2026	Common Stock	50,000	\$ 3.05	D	Â
Stock Option (right to buy)	09/30/2017 ⁽⁹⁾	09/30/2026	Common Stock	38,000	\$ 2.68	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Wingrove Theresa C/O IMMUNOGEN, INC. 830 WINTER STREET WALTHAM, MA 02451	Â	Â	Â VP of Regulatory Affairs	Â

Signatures

/s/ Craig Barrows, attorney
in fact

12/16/2016

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) All options exercisable as of filing date.

(2) All options exercisable as of filing date.

(3) All options exercisable as of filing date.

(4) All options exercisable as of filing date.

(5) 26,667 options exercisable as of filing date and 13,333 shares exercisable commencing on July 17, 2017.

Edgar Filing: IMMUNOGEN INC - Form 3

- (6) 16,000 options exercisable as of filing date, 16,000 shares exercisable commencing on July 13, 2017, and 16,000 shares exercisable commencing on July 13, 2018.
- (7) Exercisable as to 1,334 shares commencing on June 1, 2017, 1,333 shares commencing on June 1, 2018, and 1,333 shares commencing on June 1, 2019.
- (8) Exercisable as to 16,667 shares commencing on July 18, 2017, 16,667 shares commencing on July 18, 2018, and 16,666 shares commencing on July 18, 2019.
- (9) Exercisable as to 12,667 shares commencing on September 30, 2017, 12,667 shares commencing on September 30, 2018, and 12,666 shares commencing on September 30, 2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.